198 related articles for article (PubMed ID: 31292803)
1. Noscapine, a Non-addictive Opioid and Microtubule-Inhibitor in Potential Treatment of Glioblastoma.
Altinoz MA; Topcu G; Hacimuftuoglu A; Ozpinar A; Ozpinar A; Hacker E; Elmaci İ
Neurochem Res; 2019 Aug; 44(8):1796-1806. PubMed ID: 31292803
[TBL] [Abstract][Full Text] [Related]
2. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth.
Landen JW; Hau V; Wang M; Davis T; Ciliax B; Wainer BH; Van Meir EG; Glass JD; Joshi HC; Archer DR
Clin Cancer Res; 2004 Aug; 10(15):5187-201. PubMed ID: 15297423
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma.
Aneja R; Vangapandu SN; Lopus M; Chandra R; Panda D; Joshi HC
Mol Pharmacol; 2006 Jun; 69(6):1801-9. PubMed ID: 16517755
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of microtubule-interfering halogenated noscapine analogs that perturb mitosis in cancer cells followed by cell death.
Aneja R; Vangapandu SN; Lopus M; Viswesarappa VG; Dhiman N; Verma A; Chandra R; Panda D; Joshi HC
Biochem Pharmacol; 2006 Aug; 72(4):415-26. PubMed ID: 16780803
[TBL] [Abstract][Full Text] [Related]
5. Insights into the structure and tubulin-targeted anticancer potential of N-(3-bromobenzyl) noscapine.
Cheriyamundath S; Mahaddalkar T; Reddy Nagireddy PK; Sridhar B; Kantevari S; Lopus M
Pharmacol Rep; 2019 Feb; 71(1):48-53. PubMed ID: 30465924
[TBL] [Abstract][Full Text] [Related]
6. Structural Basis of Noscapine Activation for Tubulin Binding.
Oliva MA; Prota AE; Rodríguez-Salarichs J; Bennani YL; Jiménez-Barbero J; Bargsten K; Canales Á; Steinmetz MO; Díaz JF
J Med Chem; 2020 Aug; 63(15):8495-8501. PubMed ID: 32657585
[TBL] [Abstract][Full Text] [Related]
7. Novel third-generation water-soluble noscapine analogs as superior microtubule-interfering agents with enhanced antiproliferative activity.
Henary M; Narayana L; Ahad S; Gundala SR; Mukkavilli R; Sharma V; Owens EA; Yadav Y; Nagaraju M; Hamelberg D; Tandon V; Panda D; Aneja R
Biochem Pharmacol; 2014 Nov; 92(2):192-205. PubMed ID: 25124704
[TBL] [Abstract][Full Text] [Related]
8. CYLD Regulates Noscapine Activity in Acute Lymphoblastic Leukemia via a Microtubule-Dependent Mechanism.
Yang Y; Ran J; Sun L; Sun X; Luo Y; Yan B; Tala ; Liu M; Li D; Zhang L; Bao G; Zhou J
Theranostics; 2015; 5(7):656-66. PubMed ID: 25897332
[TBL] [Abstract][Full Text] [Related]
9. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation.
Zhou J; Gupta K; Aggarwal S; Aneja R; Chandra R; Panda D; Joshi HC
Mol Pharmacol; 2003 Apr; 63(4):799-807. PubMed ID: 12644580
[TBL] [Abstract][Full Text] [Related]
10. Taking aim at a dynamic target: Noscapinoids as microtubule-targeted cancer therapeutics.
Lopus M; Naik PK
Pharmacol Rep; 2015 Feb; 67(1):56-62. PubMed ID: 25560576
[TBL] [Abstract][Full Text] [Related]
11. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses.
Ke Y; Ye K; Grossniklaus HE; Archer DR; Joshi HC; Kapp JA
Cancer Immunol Immunother; 2000 Jul; 49(4-5):217-25. PubMed ID: 10941904
[TBL] [Abstract][Full Text] [Related]
12. A Comprehension into Target Binding and Spatial Fingerprints of Noscapinoid Analogues as Inhibitors of Tubulin.
Mandavi S; Verma SK; Banjare L; Dubey A; Bhatt R; Thareja S; Jain AK
Med Chem; 2021; 17(6):611-622. PubMed ID: 31951171
[TBL] [Abstract][Full Text] [Related]
13. Insight into the Tubulin-Targeted Anticancer Potential of Noscapine and its Structural Analogs.
Kumar S; Sagar B; Gaur A; Shukla S; Pandey E; Gulati S
Anticancer Agents Med Chem; 2023; 23(6):624-641. PubMed ID: 35927808
[TBL] [Abstract][Full Text] [Related]
14. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma.
Landen JW; Lang R; McMahon SJ; Rusan NM; Yvon AM; Adams AW; Sorcinelli MD; Campbell R; Bonaccorsi P; Ansel JC; Archer DR; Wadsworth P; Armstrong CA; Joshi HC
Cancer Res; 2002 Jul; 62(14):4109-14. PubMed ID: 12124349
[TBL] [Abstract][Full Text] [Related]
15. Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
DeBono A; Capuano B; Scammells PJ
J Med Chem; 2015 Aug; 58(15):5699-727. PubMed ID: 25811651
[TBL] [Abstract][Full Text] [Related]
16. A review on noscapine, and its impact on heme metabolism.
Singh H; Singh P; Kumari K; Chandra A; Dass SK; Chandra R
Curr Drug Metab; 2013 Mar; 14(3):351-60. PubMed ID: 22935070
[TBL] [Abstract][Full Text] [Related]
17. 7-Diethylamino-3(2'-benzoxazolyl)-coumarin is a novel microtubule inhibitor with antimitotic activity in multidrug resistant cancer cells.
Kim SN; Kim NH; Park YS; Kim H; Lee S; Wang Q; Kim YK
Biochem Pharmacol; 2009 Jun; 77(12):1773-9. PubMed ID: 19428332
[TBL] [Abstract][Full Text] [Related]
18. Induction of acetylation and bundling of cellular microtubules by 9-(4-vinylphenyl) noscapine elicits S-phase arrest in MDA-MB-231 cells.
Cheriyamundath S; Mahaddalkar T; Kantevari S; Lopus M
Biomed Pharmacother; 2017 Feb; 86():74-80. PubMed ID: 27939522
[TBL] [Abstract][Full Text] [Related]
19. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells.
Ye K; Ke Y; Keshava N; Shanks J; Kapp JA; Tekmal RR; Petros J; Joshi HC
Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1601-6. PubMed ID: 9465062
[TBL] [Abstract][Full Text] [Related]
20. Antimitotic inhibitors.
Campos SM; Dizon DS
Hematol Oncol Clin North Am; 2012 Jun; 26(3):607-28, viii-ix. PubMed ID: 22520982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
